The regulatory environment for tirzepatide has changed substantially since the FDA confirmed that the tirzepatide injection drug shortage has been resolved. This development is significant for MEDVi, a telehealth platform that provides access to GLP-1 weight loss medications, which has been navigating a challenging market landscape.
MEDVi has positioned itself as a competitive player in the weight loss medication space, offering compounded GLP-1 injections starting at $179 for the first month, with refills priced at $299 per month. In contrast, the branded Ozempic injection is listed at a staggering $1,999 per month, highlighting the cost-effective alternatives MEDVi provides.
In 2025, MEDVi reported an impressive $401 million in sales, and projections indicate that this figure could soar to $1.8 billion in 2026. This rapid growth is attributed to the strategic use of AI tools and partnerships, as noted by CEO Matthew Gallagher, who remarked, “Growth was insane.”
MEDVi’s business model includes a conditional refund policy for weight loss after five months, which requires a minimum commitment before a refund can be requested. This policy reflects the company’s confidence in the efficacy of its offerings, although it also underscores the time it takes for patients to acclimate to GLP-1 medications, as noted by healthcare professionals.
As MEDVi continues to expand its customer base—from just 300 customers in its first month to 1,300 in the second—its operational strategies and pricing models will be closely watched by industry observers. The company operates from its headquarters in Newark, DE, and is structured as a Delaware corporation.
With the resolution of the tirzepatide shortage, MEDVi is poised to capture a larger share of the market, appealing to consumers seeking effective weight loss solutions through telehealth. The evaluating clinician retains the decision to prescribe, ensuring that patient care remains a priority amidst the company’s growth.
Looking ahead, industry analysts anticipate that MEDVi’s innovative approach and competitive pricing will further solidify its position in the telehealth sector, particularly as demand for weight loss medications continues to rise. The company’s ability to adapt to regulatory changes and market dynamics will be crucial in maintaining its momentum.
